Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.56 |
| ▸ | PARG | Q86W56 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 3/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31743772 | 0.93 | KMT2A (0.60) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL14606725 | 0.92 | GBA1 (0.59) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL14606676 | 0.92 | GBA1 (0.59) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL7698041 | 0.92 | KMT2A (0.67) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL23048254 | 0.89 | GBA1 (0.55) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL16825749 | 0.89 | HTR2C (0.57) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL13796999 | 0.86 | GBA1 (0.52) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL2376303 | 0.82 | GBA1 (0.69) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL6799277 | 0.82 | GBA1 (0.69) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL4021825 | 0.82 | GBA1 (0.69) | GBA1KMT2AALDH1A1MEN1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2976339-B1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2976339-B1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2976340-B1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9957264-B2 | Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957264-B2 | Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957264-B2 | Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9725445-B2 | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725445-B2 | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725445-B2 | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160280704-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | US | disclosed |
| WO-2014035872-A1 | TRICYCLIC ALKYNES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014035872-A1 | TRICYCLIC ALKYNES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| US-20100204228-A1 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor | WYETH LLC (US) | 2010-08-12 | — | — | US | disclosed |
| US-7723332-B2 | Aryl sulfonamides useful for modulation of the progesterone receptor | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION | 2010-03-04 | — | — | US | disclosed |
| EP-2139852-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | Pharmos Corporation (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-2137145-A2 | CYANOPYRROL SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | Wyeth (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008109055-A2 | CYANOPYRROLE SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | WYETH (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008075353-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | SULT2A1, STS, SULT1A1 | GBA1 117/4885KMT2A 2371/4885ALDH1A1 245/4885 |
| US-20100204228-A1 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor | FSHR, GNRHR, CYP19A1 | GBA1 4794/4885KMT2A 399/4885ALDH1A1 946/4885 |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | PKD1, PKD2, SHBG | GBA1 4880/4885KMT2A 279/4885ALDH1A1 1586/4885 |
| US-20160280704-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | GBA1 4615/4885KMT2A 3361/4885ALDH1A1 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.